Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin
- PMID: 1656853
- PMCID: PMC284290
- DOI: 10.1128/AAC.35.6.1081
Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin
Abstract
The pharmacokinetics of tazobactam (500 mg) administered intravenously alone were compared with the pharmacokinetics of tazobactam coadministered with piperacillin (4 g), and the penetration into an inflammatory exudate in six healthy males was studied. Piperacillin influenced the pharmacokinetics of tazobactam. The mean levels of tazobactam in plasma at 4 h were 0.6 microgram/ml when it was given alone and 1.2 micrograms/ml when it was given with piperacillin (P = 0.0003). The mean total clearances of tazobactam were 203.5 and 134.2 ml/min (P = 0.035) when it was given alone and with piperacillin, respectively There were no significant differences in the elimination half lives, areas under the concentration-time curve from 0 h to infinity, or volumes of distribution. Inflammatory exudate penetration was rapid, and the mean maximum levels of tazobactam attained were 6.4 and 11.3 micrograms/ml when it was given alone or with piperacillin, respectively (P less than 0.06). The mean percent penetration of tazobactam and the area under the concentration-time curve from 0 h to infinity in inflammatory exudate were greater when tazobactam was given with piperacillin. The mean 24-h urinary recoveries of tazobactam were 63.7% +/- 7.9% when it was given alone and 56.8% +/- 2.7% when it was given with piperacillin. The explanation for the differences in the pharmacokinetics of tazobactam when it was administered alone compared with those when it was given with piperacillin was unclear.
Similar articles
-
Pharmacokinetic characteristics of piperacillin/tazobactam.Intensive Care Med. 1994 Jul;20 Suppl 3:S14-20. doi: 10.1007/BF01745246. Intensive Care Med. 1994. PMID: 7962984 Review.
-
Pharmacokinetics and tissue penetration of tazobactam and piperacillin in patients undergoing colorectal surgery.Antimicrob Agents Chemother. 1992 Sep;36(9):1997-2004. doi: 10.1128/AAC.36.9.1997. Antimicrob Agents Chemother. 1992. PMID: 1329637 Free PMC article.
-
Determination of free interstitial concentrations of piperacillin-tazobactam combinations by microdialysis.J Antimicrob Chemother. 1998 Dec;42(6):769-78. doi: 10.1093/jac/42.6.769. J Antimicrob Chemother. 1998. PMID: 10052901
-
Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam.Pharmacotherapy. 2002 May;22(5):569-77. doi: 10.1592/phco.22.8.569.33209. Pharmacotherapy. 2002. PMID: 12013355 Clinical Trial.
-
Pharmacokinetics and tissue penetration of piperacillin/tazobactam with particular reference to its potential in abdominal and soft tissue infections.Eur J Surg Suppl. 1994;(573):39-44. Eur J Surg Suppl. 1994. PMID: 7524794 Review.
Cited by
-
Real-Life Experience of Continuously Infused Ceftolozane/Tazobactam in Patients with Bronchiectasis and Multidrug-Resistant Pseudomonas aeruginosa Infection in the Outpatient Setting.Antibiotics (Basel). 2023 Jul 21;12(7):1214. doi: 10.3390/antibiotics12071214. Antibiotics (Basel). 2023. PMID: 37508309 Free PMC article.
-
A high-resolution screen identifies a preexisting beta-lactam that specifically treats Lyme disease in mice.Sci Transl Med. 2025 Apr 23;17(795):eadr9091. doi: 10.1126/scitranslmed.adr9091. Epub 2025 Apr 23. Sci Transl Med. 2025. PMID: 40267215 Free PMC article.
-
Tolerability, Safety, Pharmacokinetics and Drug Interaction of Cefotaxime Sodium-Tazobactam Sodium Injection (6:1) Following Single and Multiple Intravenous Doses in Chinese Healthy Subjects.Front Pharmacol. 2020 Jul 8;11:1033. doi: 10.3389/fphar.2020.01033. eCollection 2020. Front Pharmacol. 2020. PMID: 32733255 Free PMC article.
-
Evaluation of efficacy and tolerability of cefotaxime and sulbactam versus cefepime and tazobactam in patients of urinary tract infection-a prospective comparative study.J Clin Diagn Res. 2014 Nov;8(11):HC05-8. doi: 10.7860/JCDR/2014/9742.5090. Epub 2014 Nov 20. J Clin Diagn Res. 2014. PMID: 25584242 Free PMC article.
-
Penetration of piperacillin-tazobactam into bronchial secretions after multiple doses to intensive care patients.Antimicrob Agents Chemother. 1994 Dec;38(12):2780-4. doi: 10.1128/AAC.38.12.2780. Antimicrob Agents Chemother. 1994. PMID: 7695262 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases